A series of events took John L. Marshall, MD, down his path of becoming a gastrointestinal oncology leader, with a drive that has also solidified him on the patient journey and enhancing their quality of care.
A humble mindset of the contributions he has made to genitourinary cancer care, Christopher J. Logothetis, MD, is also working to shape the next generation’s…
MDA, 5th Surgical Oncology Advanced Practitioner (SOAP) Conference, 4/24/2025 7:00:00 AM – 4/26/2025 5:30:00 PM, The SOAP (Surgical Oncology Advanced Practitioner) Conference aims to foster…
The FDA has approved tislelizumab plus chemotherapy for unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.
During the 66th American Society of Hematology Annual Meeting and Exposition, investigators revealed early-phase 1 data evaluating various BTK degraders that leverage different strategies to…
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
AACR is hosting a workshop with the FDA on January 16, 2025, to discuss the considerations for routine testing of DPD deficiency before treatment with…
Felipe Batalini, MD, and Alberto Montero, MD, MBA, CPHQ, detail how allosteric inhibitors targeting PIK3CA such as STX-478 may reduce toxicities seen with orthosteric inhibitors.
Görüşmek dileğiyle… Değerli Meslektaşlarımız, Derin saygılarımızla, sizleri 16-20 Mayıs 2025 tarihleri arasında, Antalya’nın gözde mekanlarından Susesi Otel’de gerçekleştireceğimiz “XX. Ulusal ve III. Uluslararası Türk Kolon…
Researchers sought to determine if HRQoL measures differ with gilteritinib compared with placebo in patients with AML.
